Kidney Failure, Chronic — Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Citation(s)
A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) to Eliminate Donor Specific HLA Antibodies (DSAs) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Renal Transplant